Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology · HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Understanding Your Diagnosis of Tropical Spastic Paraparesis (HAM/TSP)

At a Glance

HAM/TSP is a rare, slowly progressive spinal cord disorder linked to HTLV-1 infection. Immune inflammation—not direct viral destruction—damages the cord, causing leg stiffness, walking problems, bladder symptoms, sensory changes, and lower-back pain; sudden worsening needs urgent evaluation.

Receiving a diagnosis of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) often marks the end of a long and confusing journey. Because this condition is rare and progresses slowly, many patients spend months or even years visiting different specialists before the link to the HTLV-1 virus is finally made [1][2].

While it is natural to feel overwhelmed, understanding the biology of the condition, how it differs from other viral complications, and how it is transmitted can help you navigate your care.

A Rare Complication of a Common Virus

The Human T-cell Lymphotropic Virus Type 1 (HTLV-1) is a retrovirus that affects an estimated 5 to 10 million people worldwide [3]. However, the vast majority of people with the virus—about 95%—remain asymptomatic carriers, meaning they never develop related illnesses [4].

HAM/TSP occurs in only a small fraction of those infected, with estimates ranging from 0.5% to 5% [5][6]. It is much more common in specific geographic “hotspots” where the virus has been present for generations, including:

  • The Caribbean [7]
  • South America (particularly Brazil and Peru) [8]
  • Southwestern Japan [9]
  • Parts of Intertropical Africa [7]
  • Central Australia, Romania, and Northern Iran [10]

Understanding Transmission

A common and understandable concern upon diagnosis is whether you can pass the virus to others. HTLV-1 is transmitted through specific fluids, primarily blood and breast milk. It is not spread through casual contact, hugging, kissing, or sharing utensils. The main routes of transmission are:

  • Mother to Child: Primarily through prolonged breastfeeding. Discuss safe infant feeding options with your doctor if you are planning a family [11].
  • Sexual Contact: Unprotected sex can transmit the virus. Barrier methods like condoms reduce this risk.
  • Blood Exposure: Sharing needles or receiving unscreened blood transfusions. (Note: People diagnosed with HTLV-1 should not donate blood or organs).

How the Spinal Cord is Damaged

In HAM/TSP, the damage to your spinal cord is not caused by the virus “eating” your nerve cells. Instead, it is caused by your own immune system’s overreaction. This is often called bystander damage [12].

  1. Infection: The virus lives primarily in your CD4+ T cells (a type of white blood cell) [13].
  2. Infiltration: These infected cells cross the blood-brain barrier and enter the central nervous system, especially the thoracic (middle) region of the spinal cord [14].
  3. Inflammation: Once inside, the infected cells produce inflammatory chemicals. This signals other immune cells to attack [15].
  4. Damage: In the process of trying to clear the infected cells, the immune system creates a local inflammatory environment that accidentally damages the surrounding healthy nerve tissue and the protective coating of the nerves (myelin) [14][12].

Over time, this chronic inflammation leads to spinal cord atrophy (shrinking of the cord) and scarring, which interferes with the signals traveling between your brain and your lower body [16].

What to Expect: The Disease Course

For most people, HAM/TSP is a slowly progressive condition. The symptoms usually develop over several years and include [17][12]:

  • Spastic Paraparesis: This refers to stiffness and weakness in the legs that makes walking difficult.
  • Bladder Dysfunction: More than 90% of patients experience urinary symptoms, such as urgency, frequency, or difficulty emptying the bladder [18].
  • Sensory Changes: You may feel numbness, tingling, or “pins and needles” in your feet and legs.
  • Lower Back Pain: Chronic aching in the lower back is common [6].

HAM/TSP and ATL

It is important to distinguish HAM/TSP from another rare complication of the virus called Adult T-cell Leukemia/Lymphoma (ATL). While both are linked to HTLV-1, they are separate conditions. ATL is a blood cancer that can present in different forms (acute, lymphoma, chronic, or smoldering) [17][19]. Having HAM/TSP does not mean you will eventually develop ATL. The two conditions rarely overlap, though your doctor will perform routine blood tests to monitor your overall health [20].

When to Seek Urgent Medical Attention

While the typical course of HAM/TSP is slow, there are situations that require urgent medical attention. You should contact your medical team immediately or seek emergency care if you experience:

  • Sudden loss of the ability to walk, stand, or control your bladder within days or weeks [21].
  • Rapidly worsening numbness that moves up your body (a “sensory level”) [21].
  • New, severe lumps in your neck, armpits, or groin (swollen lymph nodes) [21].
  • Unexplained fever, night sweats, or rapid weight loss [21].

These “red flags” mean you need an urgent evaluation (such as an MRI or blood work) to rule out serious issues like spinal cord compression, a severe infection, or a malignancy. Do not assume these symptoms are just your HAM/TSP acting up. Treatment for acute symptoms will depend entirely on the cause; for example, corticosteroids might be used if your doctor confirms severe inflammation, but they could be dangerous if an active infection is to blame [7][22].

Common questions in this guide

What causes the spinal cord damage in HAM/TSP?
HTLV-1 infects certain immune cells that can enter the spinal cord and trigger chronic inflammation. The immune response, rather than the virus directly destroying nerve cells, damages nearby nerve tissue and myelin, the protective coating around nerves.
How can HTLV-1 be transmitted, and can I spread it through everyday contact?
HTLV-1 can spread through infected blood, prolonged breastfeeding, sexual contact, shared needles, or unscreened blood transfusions. It is not spread by hugging, kissing, sharing utensils, or other casual contact; condoms can reduce sexual transmission, and people with HTLV-1 should not donate blood or organs.
What symptoms are typical of HAM/TSP?
HAM/TSP usually worsens slowly over years, causing stiffness and weakness in the legs that can make walking difficult. Bladder urgency, frequent urination or trouble emptying the bladder, numbness or tingling in the legs, and lower-back pain are also common.
Does having HAM/TSP mean I will develop adult T-cell leukemia/lymphoma?
No. HAM/TSP and adult T-cell leukemia/lymphoma are separate complications of HTLV-1, and having HAM/TSP does not mean that you will develop the blood cancer. The conditions rarely overlap, but your clinician may use routine blood tests to monitor your health.
When should I seek urgent care for HAM/TSP symptoms?
Seek urgent medical attention if you suddenly lose the ability to walk, stand, or control your bladder, or if numbness rapidly moves upward. New swollen lymph nodes, unexplained fever, night sweats, or rapid weight loss also need prompt evaluation because they may indicate spinal cord compression, severe infection, or another serious condition. Do not assume these changes are simply a temporary worsening of HAM/TSP.
How do clinicians confirm HAM/TSP and check for look-alike conditions?
Clinicians use established diagnostic criteria and may review your HTLV-1 results, symptoms, disease course, and disability over time. They may also check for conditions that can look similar, including multiple sclerosis, vitamin B12 deficiency, or spinal cord compression; urgent changes may prompt MRI or blood work.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific diagnostic criteria were used to confirm my diagnosis of HAM/TSP?
  2. 2.What is my HTLV-1 proviral load, and how does this impact my prognosis?
  3. 3.Have you ruled out other conditions like multiple sclerosis, Vitamin B12 deficiency, or spinal cord compression?
  4. 4.Is my current disease course considered 'typical' or 'rapidly progressive'?
  5. 5.Given my symptoms, should I be screened for Adult T-cell Leukemia/Lymphoma (ATL)?
  6. 6.What are my current Osame Motor Disability and Expanded Disability Status Scale (EDSS) scores, and how will we track these over time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Multiple spotty lesions of the spinal cord in a Chinese patient with human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis.

    Gao H, Ye X, Cai R, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2018; (68()):1-3 doi:10.1016/j.ijid.2017.12.022.

    PMID: 29292042
  2. 2

    Expanding the neurological spectrum of HTLV-1 beyond HAM/TSP: a contemporary perspective.

    Araujo AQC, Silva MTT

    Lancet regional health. Americas 2026; (55()):101347 doi:10.1016/j.lana.2025.101347.

    PMID: 41551295
  3. 3

    The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine.

    Tu JJ, Maksimova V, Ratner L, Panfil AR

    Frontiers in microbiology 2022; (13()):897346 doi:10.3389/fmicb.2022.897346.

    PMID: 35602078
  4. 4

    T cell receptor repertoire analysis in HTLV-1-associated diseases.

    Clauze A, Enose-Akahata Y, Jacobson S

    Frontiers in immunology 2022; (13()):984274 doi:10.3389/fimmu.2022.984274.

    PMID: 36189294
  5. 5

    Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study.

    Tanajura D, Castro N, Oliveira P, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; (61(1)):49-56 doi:10.1093/cid/civ229.

    PMID: 25820277
  6. 6

    Immunopathogenesis and Cellular Interactions in Human T-Cell Leukemia Virus Type 1 Associated Myelopathy/Tropical Spastic Paraparesis.

    Aghajanian S, Teymoori-Rad M, Molaverdi G, Mozhgani SH

    Frontiers in microbiology 2020; (11()):614940 doi:10.3389/fmicb.2020.614940.

    PMID: 33414779
  7. 7

    Particularities of Neurological Manifestations in Adult T-Cell Leukemia/Lymphoma: Need for a Multidisciplinary Approach-A Narrative Review.

    Iordan I, Onisâi M, Vlădăreanu AM, et al.

    Medicina (Kaunas, Lithuania) 2022; (58(11)) doi:10.3390/medicina58111553.

    PMID: 36363509
  8. 8

    Human T-Cell Lymphotropic Virus Type 1 and associated diseases in Latin America.

    Eusebio-Ponce E, Candel FJ, Anguita E

    Tropical medicine & international health : TM & IH 2019; (24(8)):934-953 doi:10.1111/tmi.13278.

    PMID: 31183938
  9. 9

    Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

    Legrand N, McGregor S, Bull R, et al.

    Clinical microbiology reviews 2022; (35(2)):e0007821 doi:10.1128/cmr.00078-21.

    PMID: 35195446
  10. 10

    Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and globally.

    Yoshida N, Hida A, Sakata R

    Leukemia research 2025; (150()):107654 doi:10.1016/j.leukres.2025.107654.

    PMID: 39904095
  11. 11

    Early Onset of HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T-cell Leukemia/Lymphoma (ATL): Systematic Search and Review.

    Oliveira PD, Kachimarek AC, Bittencourt AL

    Journal of tropical pediatrics 2018; (64(2)):151-161 doi:10.1093/tropej/fmx039.

    PMID: 28582585
  12. 12

    Role of Integrin Signaling Activation on the Development of Human T Cell Leukemia Virus-1 (HTLV-1)-Associated Myelopathy/Tropical Spastic Paraparesis: Its Relationship to HTLV-1-Infected CD4+ T Cell Transmigrating Activity into the Tissues.

    Nakamura T, Satoh K, Nakamura H, et al.

    AIDS research and human retroviruses 2018; (34(4)):331-336 doi:10.1089/AID.2017.0261.

    PMID: 29400072
  13. 13

    Molecular Studies of HTLV-1 Replication: An Update.

    Martin JL, Maldonado JO, Mueller JD, et al.

    Viruses 2016; (8(2)).

    PMID: 26828513
  14. 14

    Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis.

    Nozuma S, Kubota R, Jacobson S

    Journal of neurovirology 2020; (26(5)):652-663 doi:10.1007/s13365-020-00881-w.

    PMID: 32705480
  15. 15

    HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP.

    Yamano Y, Coler-Reilly A

    Journal of neuroimmunology 2017; (304()):51-55 doi:10.1016/j.jneuroim.2016.08.012.

    PMID: 27542993
  16. 16

    Cerebral and spinal cord changes observed through magnetic resonance imaging in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: a systematic review.

    Bastos Ferreira AP, do Nascimento ADFS, Sampaio Rocha-Filho PA

    Journal of neurovirology 2022; (28(1)):1-16 doi:10.1007/s13365-021-01043-2.

    PMID: 34981435
  17. 17

    Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis.

    Nozuma S, Jacobson S

    Frontiers in microbiology 2019; (10()):885 doi:10.3389/fmicb.2019.00885.

    PMID: 31105674
  18. 18

    Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T-cell leukemia virus type I-associated myelopathy/tropical spastic paraparesis.

    Kumekawa T, Akaihata H, Natsuya H, et al.

    IJU case reports 2024; (7(6)):438-441 doi:10.1002/iju5.12773.

    PMID: 39498183
  19. 19

    Regulation of HTLV-1 transformation.

    Ernzen KJ, Panfil AR

    Bioscience reports 2022; (42(3)) doi:10.1042/BSR20211921.

    PMID: 35169839
  20. 20

    Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis.

    Nagasaka M, Yamagishi M, Yagishita N, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2020; (117(21)):11685-11691 doi:10.1073/pnas.1920346117.

    PMID: 32393644
  21. 21

    A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma: A case report and review of the literature.

    Tamaki K, Mera H, Takeshita S, et al.

    Medicine 2021; (100(40)):e27450 doi:10.1097/MD.0000000000027450.

    PMID: 34622865
  22. 22

    Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy.

    Mashkani B, Jalili Nik M, Rezaee SA, Boostani R

    Expert review of neurotherapeutics 2023; (23(12)):1233-1248 doi:10.1080/14737175.2023.2272639.

    PMID: 37933802

This page explains HAM/TSP, HTLV-1 transmission, and warning signs for informational purposes only; it is not medical advice. Your neurologist or HTLV-1 care team should interpret your diagnosis and advise you about urgent symptoms.

Get notified when new evidence is published on Tropical spastic paraparesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.